Dermatology · Investigational
Biopeptide CL (Palmitoyl Tripeptide-5)
No lawful US pathway
01 · Overview
Palmitoyl Tripeptide-5 is a synthetic lipopeptide consisting of a tripeptide sequence conjugated to palmitic acid to improve skin delivery. Its suppliers describe it as mimicking thrombospondin-1, a matricellular protein that activates TGF-beta, to stimulate type I and III collagen production in dermal fibroblasts, but this mechanism has not been confirmed in independent peer-reviewed studies.
It is used in cosmetics for photoaging and skin firmness, and a review of products for sensitive skin found that supporting data for such peptides come mostly from patents and supplier brochures (PMID 34451799).
02 · Research summary & key findings
No independent peer-reviewed in vitro studies of palmitoyl tripeptide-5 alone on collagen gene expression or matrix metalloproteinase activity were found. In humans it has been tested only in combination products: a 12-week uncontrolled study of microneedle patches containing several peptides including palmitoyl tripeptide-5 reported fewer fine lines and increased skin density (PMID 31134751), and a 28-day study of collagen nanoparticles carrying the peptide reported improved hydration, elasticity, and wrinkle measures (PMID 39383579). The peptide's own contribution cannot be separated, and placebo-controlled trials of the peptide alone are lacking.
03 · Regulatory status
Biopeptide CL (Palmitoyl Tripeptide-5) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Biopeptide CL (Palmitoyl Tripeptide-5) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 1 FDA-approved compound in Dermatology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Biopeptide CL (Palmitoyl Tripeptide-5) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study J Cosmet Dermatol, 2020. PMID 31134751
- [2]Usage of Synthetic Peptides in Cosmetics for Sensitive Skin Pharmaceuticals (Basel), 2021. PMID 34451799
- [3]Supramolecular collagen nanoparticles for anti-wrinkle, skin whitening, and moisturizing effects Colloids Surf B Biointerfaces, 2025. PMID 39383579
Primary literature
- PubMed: "Biopeptide CL"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Biopeptide CL"
Registered interventional and observational studies, including status and phase.
- PubChem: "Biopeptide CL"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Dermatology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.